Efficacy and safety of ipragliflozin and metformin for visceral fat reduction in patients with type 2 diabetes receiving treatment with dipeptidyl peptidase-4 inhibitors in Japan: a study protocol for a prospective, multicentre, blinded-endpoint phase IV randomised controlled trial (PRIME-V study)

INTRODUCTION: In Japan, dipeptidyl peptidase-4 (DPP-4) inhibitors are frequently used as the treatment of choice for patients with type 2 diabetes. In some cases, however, poor glycaemic and body weight control issues persist despite treatment with DPP-4 inhibitors. Previous researchers have reveale...

Descripción completa

Detalles Bibliográficos
Autores principales: Koshizaka, Masaya, Ishikawa, Ko, Ishikawa, Takahiro, Kobayashi, Kazuki, Takemoto, Minoru, Horikoshi, Takuro, Shimofusa, Ryota, Takahashi, Sho, Nagashima, Kengo, Sato, Yasunori, Tatsuno, Ichiro, Terano, Takashi, Hashimoto, Naotake, Kuribayashi, Nobuichi, Uchida, Daigaku, Yokote, Koutaro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2017
Materias:
Diabetes and Endocrinology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5726071/
https://www.ncbi.nlm.nih.gov/pubmed/28490565
http://dx.doi.org/10.1136/bmjopen-2016-015766

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5726071/
https://www.ncbi.nlm.nih.gov/pubmed/28490565
http://dx.doi.org/10.1136/bmjopen-2016-015766

Ejemplares similares